8-K: Qualigen Amends Marizyme Promissory Note, Increases Loan

Qualigen Therapeutics, Inc. amended its secured promissory note with Marizyme, Inc., correcting the maturity date to August 21, 2026, and increasing the principal by $75,000 to $4,526,462.18.

Summary

• Qualigen Therapeutics, Inc. (Lender) and Marizyme, Inc. (Borrower) entered into Amendment No. 1 to their Amended and Restated Secured Demand Promissory Note.
• The amendment, effective September 15, 2025, corrects the maturity date of the note to August 21, 2026.
• The principal amount outstanding was increased by $75,000, bringing the new total principal balance to $4,526,462.18.
• The additional $75,000 advance will accrue interest at the rate specified in the original Amended and Restated Note.
• All obligations under the note remain secured by the existing Security Agreement.

Sentiment

Score: 5

Explanation: The amendment is a neutral event, primarily correcting a date and providing a small additional advance. It does not significantly alter Qualigen Therapeutics, Inc.'s financial position in a positive or negative way, but it does increase exposure to Marizyme, Inc.

Positives

• The note remains secured by an existing Security Agreement, providing collateral for Qualigen Therapeutics, Inc.
• Qualigen Therapeutics, Inc. earns interest on the additional $75,000 advance.
• The maturity date is now clearly defined as August 21, 2026, providing clarity on repayment terms.

Negatives

• Qualigen Therapeutics, Inc. has increased its financial exposure to Marizyme, Inc. by an additional $75,000.
• The filing does not provide details on Marizyme, Inc.'s financial health or ability to repay the increased principal.

Risks

• Risk of default by Marizyme, Inc. on the increased principal amount of $4,526,462.18, despite the note being secured.
• The value and liquidity of the collateral securing the note are not disclosed, posing a risk if Marizyme, Inc. defaults.
• Qualigen Therapeutics, Inc.'s increased financial commitment to Marizyme, Inc. could impact its own liquidity or capital allocation for other strategic initiatives.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the corrected maturity date of the promissory note.

Management Comments

• Kevin Richardson II, Interim Chief Executive Officer of Qualigen Therapeutics, Inc., signed the amendment on behalf of the company.

Industry Context

This specific amendment to a promissory note between two companies does not directly relate to broader industry trends or competitors, but rather reflects an internal financing arrangement or a transaction with a related entity. It indicates Qualigen Therapeutics, Inc.'s role as a lender, potentially supporting a partner or subsidiary, which is a common practice in certain industry structures.

Comparison to Industry Standards

• NA

Related Party Transactions

• The filing describes a transaction between Qualigen Therapeutics, Inc. (Lender) and Marizyme, Inc. (Borrower) involving an amendment to a secured demand promissory note. The nature of the relationship beyond lender-borrower is not explicitly detailed in the filing.

Stakeholder Impact

• Shareholders: Increased financial exposure to Marizyme, Inc. by Qualigen Therapeutics, Inc., which could be a concern if Marizyme, Inc.'s financial health is weak, but also represents potential interest income. The note is secured, which mitigates some risk.

Next Steps

• Repayment of the principal amount of $4,526,462.18, along with accrued interest, by Marizyme, Inc. to Qualigen Therapeutics, Inc. on or before the maturity date of August 21, 2026.

Key Dates

Recommendation

The filing details a routine amendment to a promissory note, involving a minor increase in the loan amount and a date correction. It does not present new information that would fundamentally alter the investment thesis for Qualigen Therapeutics, Inc. The increased exposure to Marizyme, Inc. is small relative to the existing loan, and the note remains secured. Investors should continue to hold and monitor Qualigen Therapeutics, Inc.'s core business operations and overall financial performance rather than reacting to this specific administrative and minor financial adjustment.

Keywords

Qualigen Therapeutics, Marizyme, Promissory Note, Secured Debt, Loan Amendment, Financial Obligation, SEC Filing, 8-K, Debt Financing, Corporate Finance